Abstract
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and devastating disease, which is characterized by invasiveness and dissemination to the lymphatic system and distant organs. In the absence of effective screening methods considerable efforts have thus been made to identify better systemic treatments than gemcitabine, the standard of care for advanced PDAC for well over a decade. However, until now only erlotinib, an epidermal growth-factor receptor tyrosine kinase inhibitor, has demonstrated a modest survival benefit in combination with gemcitabine in a phase III clinical trial. More recently, detailed global genomic analyses have provided a snapshot of the landscape of tumor genomes by showing that they contain four high frequency mutated genes and many low frequency mutated genes that correspond to 12 core signaling pathways. Strategies to target these frequently altered genes and their pathways, or low frequency mutated genes corresponding to the “personalized genome”, offer novel therapeutic strategies. In the near future, the complete sequencing of the coding genome, together with the dramatically reduced costs of whole genome sequencing, will provide new opportunities to treat PDAC.
Keywords: Whole genome sequencing, KRAS, TP53, CDKN2A/p16, SMAD4/DPC4, hedgehog pathway, personalized genome
Current Pharmaceutical Design
Title:Novel Therapeutic Approaches in Pancreatic Cancer Based on Genomic Alterations
Volume: 18 Issue: 17
Author(s): Shinichi Yachida
Affiliation:
Keywords: Whole genome sequencing, KRAS, TP53, CDKN2A/p16, SMAD4/DPC4, hedgehog pathway, personalized genome
Abstract: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and devastating disease, which is characterized by invasiveness and dissemination to the lymphatic system and distant organs. In the absence of effective screening methods considerable efforts have thus been made to identify better systemic treatments than gemcitabine, the standard of care for advanced PDAC for well over a decade. However, until now only erlotinib, an epidermal growth-factor receptor tyrosine kinase inhibitor, has demonstrated a modest survival benefit in combination with gemcitabine in a phase III clinical trial. More recently, detailed global genomic analyses have provided a snapshot of the landscape of tumor genomes by showing that they contain four high frequency mutated genes and many low frequency mutated genes that correspond to 12 core signaling pathways. Strategies to target these frequently altered genes and their pathways, or low frequency mutated genes corresponding to the “personalized genome”, offer novel therapeutic strategies. In the near future, the complete sequencing of the coding genome, together with the dramatically reduced costs of whole genome sequencing, will provide new opportunities to treat PDAC.
Export Options
About this article
Cite this article as:
Yachida Shinichi, Novel Therapeutic Approaches in Pancreatic Cancer Based on Genomic Alterations, Current Pharmaceutical Design 2012; 18 (17) . https://dx.doi.org/10.2174/13816128112092452
DOI https://dx.doi.org/10.2174/13816128112092452 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Microalgal Fatty Acids and Their Implication in Health and Disease
Mini-Reviews in Medicinal Chemistry Identification of Drug Candidates for Breast Cancer Therapy Through Scaffold Repurposing: A Brief Review
Current Drug Research Reviews Lipids as a Target for Drugs Modulating Multidrug Resistance of Cancer Cells
Current Drug Targets Regulation of Arylamine N-Acetyltransferases
Current Drug Metabolism Pegylated Interferons for the Treatment of Chronic Hepatitis B
Recent Patents on Anti-Infective Drug Discovery Triggering PIK3CA Mutations in PI3K/Akt/mTOR Axis: Exploration of Newer Inhibitors and Rational Preventive Strategies
Current Pharmaceutical Design Identification of Azo Dye Degrading Sphingomonas Strain EMBS022 and EMBS023 Using 16S rRNA Gene Sequencing
Current Bioinformatics Virotherapy as An Approach Against Cancer Stem Cells
Current Gene Therapy New Approaches to Target the Androgen Receptor and STAT3 for Prostate Cancer Treatments
Mini-Reviews in Medicinal Chemistry The Putative Adverse Effects of Bisphenol A on Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of 3D Pharmacophore Mapping Based Virtual Screening for Identification of Novel Anticancer Agents: An Overview
Current Topics in Medicinal Chemistry The Role of B Cell Receptor Stimulation in CLL Pathogenesis
Current Pharmaceutical Design Basal Breast Cancer: A Complex and Deadly Molecular Subtype
Current Molecular Medicine Nanotechnology-Based Drug Delivery Systems for Treatment of Hyperproliferative Skin Diseases - A Review
Current Nanoscience The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine Anti-Cancer Compounds Targeted to VDAC: Potential and Perspectives
Current Medicinal Chemistry Exploiting Novel Cell Cycle Targets in the Development of Anticancer Agents
Current Cancer Drug Targets PARP Inhibitors: An Interesting Pathway also for Non-Small Cell Lung Cancer?
Current Pharmaceutical Design The Mechanism of Calcitriol in Cancer Prevention and Treatment
Current Medicinal Chemistry Adrenergic Receptors as Targets for Cancer Treatment - A Perspective for Future Studies
Current Cancer Therapy Reviews